Foley Partner Gardner Davis and Senior Counsel Danielle Whitley authored an article titled “NOL and void” in the April 5, 2010 issue of The Deal. The authors discuss a Delaware Court of Chancery decision that upheld Selectica Inc.’s selection of a shareholder rights plan, or poison pill, as a tool to protect its net operating loss carry forwards (NOLs), remarking that it is the first time that a Delaware court has reviewed a board’s decision to adopt a poison pill intended to guard NOLs. They add that the decision should not be interpreted as support for the suggestion that a board can safely adopt a poison pill in every circumstance, noting the court’s acknowledgment that shareholder rights plans must be subject to careful review.
Author(s)
Related Insights
July 2, 2025
Energy Current
Has SCOTUS Pre-decided Whether the NRC Can License Private Off-Site High-Level Nuclear Waste Storage Facilities?
On June 18, 2025, the U.S. Supreme Court, in NRC v. Texas, issued an opinion holding that the State of Texas did not have standing to…
July 2, 2025
Health Care Law Today
AI-Powered Text Messaging by Digital Health Companies: Supreme Court Raises the Stakes
Digital health companies increasingly rely on AI-powered messaging platforms, chatbots, and virtual assistants to engage patients through…
July 2, 2025
Innovative Technology Insights
AI-Powered Text Messaging by Digital Health Companies: Supreme Court Raises the Stakes
Digital health companies increasingly rely on AI-powered messaging platforms, chatbots, and virtual assistants to engage patients through…